Danaher (DHR)
Life-science and diagnostics conglomerate; the Danaher Business System acquirer. Danaher is listed on the New York Stock Exchange and reports in USD. compounders.ai reads its annual filings and shows reported operating profit next to normalized EBITA under one published rulebook, every figure linked to the filing it was read from.
- Archetype
- US industrial acquirer
- Listing
- New York Stock Exchange: DHR (listing key
NYSE-DHR) - Country
- United States
- Reporting currency
- USD
- Filing source
- SEC inline XBRL (native)
- Latest filing on record
- Form 10-K for the fiscal year ended 2025-12-31 — Danaher, filed 24 Feb 2026 (25 filings on record)
- Fiscal years published
- FY2010–FY2025
- Normalized EBITA published
- FY2025
Key figures, FY2025
Fiscal year ended 31 Dec 2025, in USD as reported. Published 20 Oct 2026 under ruleset 1.4.0; read for this page on 20 Oct 2026. Each figure links to the filing it was read from; a computed figure links to its primary citation.
| Figure | FY2025 | Source |
|---|---|---|
| Income statement | ||
| Revenue | USD 24,568 million | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · as filed |
| Reported operating profit | USD 4,690 million | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · as filed |
| Reported operating margin | 19.1% | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · computed from cited lines |
| Normalized EBITA | USD 6,387 million | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · computed from cited lines |
| Normalized EBITA margin | 26.0% | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · computed from cited lines |
| Normalized EBITDA | USD 7,137 million | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · computed from cited lines |
| Returns on capital | ||
| ROIC incl. goodwill | 8.4% | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · computed from cited lines |
| ROIC excl. goodwill | 23.5% | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:OperatingIncomeLoss · computed from cited lines |
| ROIIC, 3 years | Not published for FY2025 | |
| Balance sheet and cash | ||
| Net debt | USD 13,803 million | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:LongTermDebtNoncurrent · computed from cited lines |
| Net debt to EBITDA | 1.93x | Form 10-K for the fiscal year ended 2025-12-31 — Danaher · us-gaap:LongTermDebtNoncurrent · computed from cited lines |
| FCF before acquisitions | Not published for FY2025 | |
| FCF available to shareholders (FCFA2S) | Not published for FY2025 | |
Earlier years (FY2010–FY2024) are in the terminal's tabs below.
In the terminal
- Danaher: Financials
- Danaher: Normalization
- Danaher: Growth
- Danaher: KPIs
- Danaher: Returns
- Danaher: Sources
How the figures are made: methodology · glossary · how to cite them: citation guidelines.